Healthcare
Helix BioPharma Corp.(HBPCF)
Live Price
Offline$1.71
+0.00% today
1Y Change
+185.00%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $150.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +100.0%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Helix BioPharma Corp. (HBPCF) is a Healthcare stock with a market cap of $150.00M and listed on OTC. The stock last traded around $1.71 and up 185.0% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +100.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +100.0%, free cash flow +23.6% with operating margin 0.0% and ROIC -26.2%. Stock Foundry combines HBPCF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Jun 17, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +100.0%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Jun 17, 2026 | โ | +0.0% | โ | โ |
2026 Jun 15, 2026 | โ | +0.0% | +0.0% | โ |
2026 Mar 16, 2026 | +87.2% | +0.0% | +0.0% | +0.0% |
Benchmark Edge
HBPCF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
HBPCF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
HBPCF Max Drawdown
-1.16%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for HBPCF and SPY.
Company Overview
Helix BioPharma Corp.
Other OTC
Helix BioPharma Corp. operates as an immune-oncology company in Canada. The company is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.
- Leadership
- Thomas Mehrling
- IPO Date
- Nov 27, 2009
- Employees
- 7
- Street Address
- 401 Bay Street
- Mailing
- Toronto, ON, M5H 2Y4
- Region
- Toronto, ON, CA
- Reporting Currency
- USD
- Investor Line
- +1 905 841 2300
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 9.8
Growth
- Revenue
- 0.0%
- EPS
- +100.0%
- Free Cash Flow
- +23.6%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -36.8%
- ROIC
- -26.2%
Balance Sheet
- Debt/Equity
- 0.02
- Current Ratio
- 0.04
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.